Cargando…

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

BACKGROUND: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs) are still limited. We investigated the antitumour activity and safety profile of pazopanib – a multitarget drug with anti-angiogenic activity in patients with metastatic GEP NETs. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, H K, Choi, J Y, Kim, K-M, Kim, H, Choi, S-H, Park, S H, Park, J O, Lim, H Y, Kang, W K, Lee, J, Park, Y S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776983/ https://www.ncbi.nlm.nih.gov/pubmed/23989950 http://dx.doi.org/10.1038/bjc.2013.470

Ejemplares similares

Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors
por: Komoto, Izumi, et al.
Publicado: (2022)

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
por: Jeong, H., et al.
Publicado: (2021)

Prevalence of Sarcopenia and Impact on Survival in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours
por: Clement, Dominique S. V. M., et al.
Publicado: (2023)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
por: Ramage, John K, et al.
Publicado: (2011)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
por: Kim, Seung Tae, et al.
Publicado: (2016)

Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study
por: Kim, Hyun-Jun, et al.
Publicado: (2018)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
por: Lee, Su Jin, et al.
Publicado: (2014)

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
por: Jeung, H-C, et al.
Publicado: (2006)

Liver metastases in gastroenteropancreatic neuroendocrine tumours – treatment methods
por: Gut, Paweł
Publicado: (2020)

The Multidisciplinary Team for Gastroenteropancreatic Neuroendocrine Tumours: The Radiologist’s Challenge
por: Granata, Vincenza, et al.
Publicado: (2019)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
por: McClellan, Kristen, et al.
Publicado: (2022)

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
por: Oh, S C, et al.
Publicado: (2007)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
por: Aristizabal Prada, E T, et al.
Publicado: (2017)

Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis
por: Bongiovanni, Alberto, et al.
Publicado: (2020)

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
por: Park, S., et al.
Publicado: (2022)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience
por: Lim, Chul-Hyun, et al.
Publicado: (2017)

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
por: Yoo, Kwai Han, et al.
Publicado: (2015)

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
por: Eriksson, M., et al.
Publicado: (2021)

Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours – an analysis based on the CLARINET study
por: Meng, Yang, et al.
Publicado: (2017)

Cost‐of‐illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden—A population‐based register‐linkage study
por: Lesén, Eva, et al.
Publicado: (2019)

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Natural history and outcome in chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis
por: Chan, Doris T., et al.
Publicado: (2016)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
por: Kim, M., et al.
Publicado: (2023)

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
por: Lim, S H, et al.
Publicado: (2015)

Gastroenteropancreatic neuroendocrine tumour arising in Meckel’s diverticulum coexisting with colon adenocarcinoma
por: Katalinic, Darko, et al.
Publicado: (2014)

Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumours: a Systematic Literature Review
por: Cockburn, Katrina Clair, et al.
Publicado: (2021)

Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Reccia, Isabella, et al.
Publicado: (2023)

Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center
por: Jalbert, Jessica J., et al.
Publicado: (2020)

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Hee Sung, et al.
Publicado: (2014)

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
por: Fruehauf, John P., et al.
Publicado: (2018)

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
por: Toi, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_9erlu8ajp02ncpa9o5np85po2e